See the DrugPatentWatch profile for kymriah
How Kymriah (tisagenlecleucel) works in the body
Kymriah is a CAR T-cell therapy. It works by using a patient’s own T cells, genetically engineering them to recognize a specific marker on cancer cells, and then giving those modified cells back so they can attack the tumor.
What happens after doctors infuse Kymriah
Once infused, the engineered CAR T cells circulate and bind to cells that display the target antigen, which triggers the CAR T cells to activate. Activated CAR T cells then kill the targeted cancer cells and can expand in the body, helping sustain the anti-cancer response over time.
Why Kymriah needs the CAR design
The key step is the genetic modification that gives the T cells an artificial receptor (the CAR). That receptor is designed to recognize a cancer-associated surface marker, allowing the immune cells to identify and attack cells that would otherwise escape immune detection.
Where Kymriah fits for blood cancers
CAR T-cell therapies like Kymriah are designed for certain blood cancers where malignant cells carry the target antigen on their surface, making them reachable to CAR T cells after infusion.
Patient questions people often ask: “Is it chemotherapy?”
Kymriah is not conventional chemotherapy. It is an immunotherapy that relies on engineered immune cells to find and destroy cancer cells. Like other CAR T therapies, it can also cause immune-related side effects because the infused cells become activated in the body during the treatment response.